Open AccessPB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS‐PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA
Author(s) -
Soussain C.,
Grommes C.,
Ward R.,
Peterson C.,
Cravets M.,
Mathias A.,
Sosa J.,
Kirby B.,
Ding Z.,
Yusuf I.,
Rose M.,
Steinberg M.,
Tun H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851216.47783.78
Subject(s) - tolerability , ibrutinib , medicine , lymphoma , pharmacology , oncology , pharmacodynamics , pharmacokinetics , adverse effect , leukemia , chronic lymphocytic leukemia